ABSTRACT
A total of 186 patients who met the DSM-III criteria for schizophrenia were admitted to a double-blind randomized multicentre trial in which the efficacy and safety of remoxipride at two dose levels was compared with those of haloperidol. Over a period of six weeks the patients received remoxipride 100-300 mg/day (n = 60), remoxipride 200-600 mg/day (n = 61), or haloperidol 10-30 mg/day (n = 64). There was no significant difference between the three treated groups with regard to the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scores obtained. Remoxipride, at both dosage ranges used, thus had comparable therapeutic efficacy to that of haloperidol. In contrast, extrapyramidal symptoms occurred significantly more frequently in the group treated with haloperidol. Laboratory tests and cardiovascular investigations showed no specific drug effect in any of the treated patients. Remoxipride is thus effective in acute treatment of schizophrenia at both dosage levels and has an advantage over haloperidol in neurological acceptability.
Subject(s)
Antipsychotic Agents/administration & dosage , Benzamides/administration & dosage , Haloperidol/administration & dosage , Schizophrenia/drug therapy , Schizophrenic Psychology , Adolescent , Adult , Aged , Antipsychotic Agents/adverse effects , Benzamides/adverse effects , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Haloperidol/adverse effects , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , RemoxiprideABSTRACT
This new instrument to evaluate anxiety, the F.A.R.D. (Ferreri anxiety rating diagram - 1987) has been conceived to appreciate the repercussions of anxiety on the activity of the subject. It realizes a special image of anxiety. It has been studied, by both psychiatrists and general practitioners in 320 patients included on generalised anxiety disorders criteria (following DMS III). The validation has been realised in a study of prazepam for 81 patients. The F.A.R.D. is based upon 12 items. The factor analysis has retained 4 factors explaining 66% of the whole variance. These 4 factors composed by 3 items each are: relational, somatic, vigilance, cognitive. This new instrument, the F.A.R.D.: evaluates the intensity of anxiety, precision, the shape of anxiety, specifies sub-groups of anxiety, allows a following of evolution, appreciates the pharmaco-clinical profile of the anxiolytic drug prescribed.
Subject(s)
Anxiety Disorders/diagnosis , Personality Inventory , Adult , Aged , Anxiety Disorders/drug therapy , Anxiety Disorders/physiopathology , Evaluation Studies as Topic , Family Practice , Female , Humans , Male , Middle Aged , PsychiatryABSTRACT
We have performed a national multicentric atrial in psychiatry, collecting 546 patients with neurotic inhibition. The efficacy of carpipramine was evaluated in this disease. A transnosographic and epidemiologic analysis of this syndrome was realized on this group of out patients. The statistical study by a factorial analysis of correspondences shows the epidemiological and symptomatic characteristics of inhibition. The endpoints were DSM-III criteria of chronic anxiety, adaptation disorders and functional sexual disorders on the first axis and different types of personality on the second axis.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Benzodiazepines , Dibenzazepines/therapeutic use , Inhibition, Psychological/drug effects , Neurotic Disorders/drug therapy , Psychotropic Drugs/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Dibenzazepines/administration & dosage , Dibenzazepines/adverse effects , Drug Evaluation , Female , Humans , Male , Middle Aged , Neurotic Disorders/classificationABSTRACT
The complexity of the anxious disease does not facilitate the clinical approach. That the reason why the authors have developed a rating scale based on a descriptive symptomatology to find out a diagnosis, to rate the severity of illness and to facilitate the pharmaceutical prescription. To develop a skill needed by general practitioners as well as specialists, Prof. M. Ferreri worked with pools of medical doctors to isolate the more frequent items in the anxious symptomatology. So they pointed out a first group of 14 items. A first statistical approach was to compare the new scale with the well-known Hamilton anxiety scale by the way of a sample of 81 ratings. After a first factor analysis, a sub-group of 12 items were definitely retained. These items were split in 4 factors which permitted to present the factorial results in diagram [Acta psychiat. belg., 87, 704-713 (1987)].
Subject(s)
Anxiety Disorders/diagnosis , Psychiatric Status Rating Scales , Psychometrics , Adult , Anxiety Disorders/psychology , Factor Analysis, Statistical , Female , Humans , Male , Middle AgedABSTRACT
A national multicentric trial has included 402 depressed patients (DSM III Criteria) and has validated diagram HARD by MADRS. A constant and similar decrease in the total of the two rating scales has been shown at several times of assessment, Day 0, 10, 20, 60, and 90. High coefficents of correlation are found between HARD and MADRS. The sensitivity to change under treatment (mianserin 60 mg) is equal for the two rating scales.
Subject(s)
Depression/drug therapy , Mianserin/therapeutic use , Psychological Tests , Adult , Clinical Trials as Topic , Depression/diagnosis , Depressive Disorder/diagnosis , Depressive Disorder/drug therapy , Female , Humans , Male , Middle AgedABSTRACT
In the study reported here 73 ambulatory patients with neurotic or reactional anxiety state were treated with bromazepam (Lexomil) 6 to 12 mg/24 hours in 3 divided doses with a double dose at night. Treatment lasted from 28 days (8 patients) to 60 days or more (42 patients). Results were excellent or good in 43 cases, with rapid improvement in the psychic component of anxiety. Twelve of the 15 patient s who took bromazepam 4 hours before going to bed plus a hypnotic at night showed improvement in the quality of sleep. During weaning of ambulatory alcoholic subjects by gradual withdrawal of alcoholic beverages, bromazepam proved useful in reducing the anxiety load. The drug was generally well tolerated.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/drug therapy , Bromazepam/therapeutic use , Adult , Aged , Alcoholism/psychology , Anxiety Disorders/psychology , Bromazepam/adverse effects , Drug Evaluation , Female , Humans , Male , Middle Aged , Substance Withdrawal Syndrome/drug therapySubject(s)
Psychology, Adolescent , Self Concept , Adolescent , Female , Humans , Male , Masturbation , Parent-Child Relations , Sexual MaturationABSTRACT
The authors are focusing on the absence of inhibition of H reflex in depressed patients compared with normal subjects, and this during the voluntary hyperventilation and the zazzo "barrage" tests.
